InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD’s mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: embolic showers, restenosis, and late stent thrombosis. InspireMD intends to pursue applications of its innovative technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.
Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
DarioHealth is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue.
MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.
Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases. The early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system. GentiBio is a Seattle, Washington-headquartered company launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker.
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.
Chemomab Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on discovering innovative treatments for fibrosis-related diseases that have significant unmet medical needs. Chemomab's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of CCL24, a soluble protein that plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently under clinical development, with a particular emphasis on treating orphan diseases such as Primary Sclerosing Cholangitis and Systemic Sclerosis. The company is conducting three Phase 2 clinical trials for CM-101 in various fibrotic indications and anticipates reporting results from these studies in the near future.
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.
MobileODT builds small, smart, connected visual diagnostic tools to enable any health provider, anywhere, to conduct examinations on the level of an expert practitioner. Empowering less-trained providers increases the reach of health systems, reducing costs, and improving outcomes. The Enhanced Visual Assessment (EVA) System is our first product, an FDA cleared internet-connected mobile colposcope and is growing rapidly in market share in the US, across Africa, and India. It is used in the world’s harshest environments and receives accolades from clinicians in the world’s leading hospitals (MD Anderson, Mount Sinai, Apollo). EVA has been used for over 40,000 procedures in 29 countries. Our customers include the world’s leading hospital groups West and East, and our fastest-growing market is the US, where we are becoming the standard for visualization (+20% of hospitals in New York State who offer Sexual Assault Forensic Examinations use EVA). We are growing rapidly in new geographies and have in the pipeline additional visual-based applications, including ENT, Oral disease, and Skin.
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases. The early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system. GentiBio is a Seattle, Washington-headquartered company launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker.
TytoCare is a mobile-health platform and device, that allows anyone to perform self-physical examination and remote diagnosis. Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit and include a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use.
Chemomab Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on discovering innovative treatments for fibrosis-related diseases that have significant unmet medical needs. Chemomab's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of CCL24, a soluble protein that plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently under clinical development, with a particular emphasis on treating orphan diseases such as Primary Sclerosing Cholangitis and Systemic Sclerosis. The company is conducting three Phase 2 clinical trials for CM-101 in various fibrotic indications and anticipates reporting results from these studies in the near future.
ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.
Foamix Pharmaceuticals is a specialty pharmaceutical company based in Bridgewater, New Jersey, that focuses on the development and commercialization of proprietary topical drugs for dermatological conditions, as well as for ophthalmologic and gynecologic applications. Founded in 2014, the company utilizes its Molecule Stabilizing Technology platform to create innovative foam-based formulations. Its lead product, a first-in-class Topical Minocycline Foam, targets significant markets in dermatology and ophthalmology, having shown high efficacy and favorable safety in clinical trials for conditions such as acne and impetigo. Foamix's pipeline includes multiple drug candidates aimed at treating various skin conditions, including FMX101, FMX102, FMX103, and FDX104. The company is also engaged in development and licensing agreements with other pharmaceutical firms, enhancing its reach in the healthcare market.
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
Foamix Pharmaceuticals is a specialty pharmaceutical company based in Bridgewater, New Jersey, that focuses on the development and commercialization of proprietary topical drugs for dermatological conditions, as well as for ophthalmologic and gynecologic applications. Founded in 2014, the company utilizes its Molecule Stabilizing Technology platform to create innovative foam-based formulations. Its lead product, a first-in-class Topical Minocycline Foam, targets significant markets in dermatology and ophthalmology, having shown high efficacy and favorable safety in clinical trials for conditions such as acne and impetigo. Foamix's pipeline includes multiple drug candidates aimed at treating various skin conditions, including FMX101, FMX102, FMX103, and FDX104. The company is also engaged in development and licensing agreements with other pharmaceutical firms, enhancing its reach in the healthcare market.
MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.
TytoCare is a mobile-health platform and device, that allows anyone to perform self-physical examination and remote diagnosis. Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit and include a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use.
Chemomab Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on discovering innovative treatments for fibrosis-related diseases that have significant unmet medical needs. Chemomab's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of CCL24, a soluble protein that plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently under clinical development, with a particular emphasis on treating orphan diseases such as Primary Sclerosing Cholangitis and Systemic Sclerosis. The company is conducting three Phase 2 clinical trials for CM-101 in various fibrotic indications and anticipates reporting results from these studies in the near future.
Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries. The company was founded in 2003 and headquartered in HaMerkaz, Israel.
RDD is focused on developing targeted therapeutics and delivery systems for treating diseases of the anorectal region and lower gastrointestinal tract. In order to treat diseases in this challenging area, drugs require special formulation and delivery/application techniques to address wide variations in anatomy and physiology.
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
MobileODT builds small, smart, connected visual diagnostic tools to enable any health provider, anywhere, to conduct examinations on the level of an expert practitioner. Empowering less-trained providers increases the reach of health systems, reducing costs, and improving outcomes. The Enhanced Visual Assessment (EVA) System is our first product, an FDA cleared internet-connected mobile colposcope and is growing rapidly in market share in the US, across Africa, and India. It is used in the world’s harshest environments and receives accolades from clinicians in the world’s leading hospitals (MD Anderson, Mount Sinai, Apollo). EVA has been used for over 40,000 procedures in 29 countries. Our customers include the world’s leading hospital groups West and East, and our fastest-growing market is the US, where we are becoming the standard for visualization (+20% of hospitals in New York State who offer Sexual Assault Forensic Examinations use EVA). We are growing rapidly in new geographies and have in the pipeline additional visual-based applications, including ENT, Oral disease, and Skin.
Mitoconix Bio Ltd, founded in 2016 and based in Jerusalem, Israel, is focused on developing innovative therapies aimed at enhancing mitochondrial health to address neurodegenerative diseases. The company seeks to improve mitochondrial functions, which are crucial for energy production, cellular metabolism, and maintaining cellular balance. Mitochondria play a vital role in neuronal health through processes such as fission and fusion, which are essential for their motility and functionality. Disruptions in these processes can lead to decreased energy production, increased oxidative stress, and cell death. Mitoconix's lead drug is a pioneering inhibitor that targets pathological mitochondrial fragmentation and dysfunction, demonstrating efficacy in animal models of Huntington’s and Parkinson’s diseases, as well as beneficial effects in patient-derived cells associated with these and Alzheimer’s disease.
Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions. The company was founded in 2012 and is based in Lebanon, New Hampshire.
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.
Chemomab Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on discovering innovative treatments for fibrosis-related diseases that have significant unmet medical needs. Chemomab's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of CCL24, a soluble protein that plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently under clinical development, with a particular emphasis on treating orphan diseases such as Primary Sclerosing Cholangitis and Systemic Sclerosis. The company is conducting three Phase 2 clinical trials for CM-101 in various fibrotic indications and anticipates reporting results from these studies in the near future.
Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.
Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.
MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.
Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.
Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.
Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions. The company was founded in 2012 and is based in Lebanon, New Hampshire.
TytoCare is a mobile-health platform and device, that allows anyone to perform self-physical examination and remote diagnosis. Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit and include a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use.
Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.
Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries. The company was founded in 2003 and headquartered in HaMerkaz, Israel.
Medigus Ltd. is a medical device company based in Omer, Israel, specializing in minimally invasive endo-surgical tools and direct visualization technology. Established in 1999, Medigus focuses on innovative endoscopic procedures, particularly for the treatment of gastroesophageal reflux disease (GERD), a prevalent chronic condition. The company’s flagship product, the Medigus Ultrasonic Surgical Endostapler (MUSE), is a single-use device designed for the incisionless treatment of GERD. This system integrates a miniaturized video camera, surgical stapler, and ultrasonic alignment technology, allowing gastroenterologists to perform a partial anterior fundoplication without traditional surgical methods, thus transforming GERD treatment. Additionally, Medigus develops a range of micro video cameras under the micro ScoutCam brand, catering to both medical and industrial applications, while also designing endoscopy systems for partner companies based on its proprietary technologies.
Keystone Heart aspires to be the world leader in embolic cerebral protection for cardiovascular procedures. To develop and manufacture cerebral protection devices, focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, AF ablation and other structural heart procedures. Cerebral function is the essence of quality of life. Preserving brain reserve throughout medical procedures is a key component to procedural success and patient care.
TytoCare is a mobile-health platform and device, that allows anyone to perform self-physical examination and remote diagnosis. Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit and include a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use.
Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, focusing on gastrointestinal and infectious diseases. The company markets several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. RedHill is also engaged in late-stage clinical development programs, which include RHB-204 for pulmonary nontuberculous mycobacteria infections, RHB-104 for Crohn's disease, and RHB-102 (Bekinda) for acute gastroenteritis and gastritis. Additionally, it is developing opaganib, a selective inhibitor with ongoing studies for various conditions, including COVID-19 and cancer. Other investigational products include RHB-107, aimed at treating cancer and inflammatory gastrointestinal diseases, and RHB-106, an encapsulated bowel preparation. Established in 2009, RedHill aims to innovate and enhance treatment options in its specialized fields.
Treato Ltd. operates a health information platform that aggregates and analyzes patient experiences sourced from the Internet, particularly from social media sites and forums. The platform provides valuable insights for patients, healthcare professionals, pharmaceutical companies, and other healthcare organizations. By employing advanced Natural Language Processing, Treato extracts relevant information from the vast amount of patient-written health experiences, creating a comprehensive understanding of public sentiment regarding medications and health conditions. Treato also offers Treato Pharma, a specialized service that delivers real-time analytics and insights to pharmaceutical marketers, helping them interpret patient opinions, understand competitive dynamics, and enhance patient engagement. Founded in 2008 and based in Yehud, Israel, Treato serves as a critical resource for both consumers and the healthcare industry, with its advertising-free consumer site attracting hundreds of thousands of users weekly.
Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions. The company was founded in 2012 and is based in Lebanon, New Hampshire.
BioLineRx is a clinical-stage, publicly traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.
cCAM Biotherapeutics Ltd. is a clinical-stage company focused on the discovery and development of novel immunotherapies for cancer treatment. Founded in 2010 and based in Misgav, Israel, the company is advancing its lead candidate, CM-10, an immunomodulatory antibody designed to counteract the immunosuppressive effects of CEACAM1, a protein utilized by cancer cells. By inhibiting this protein, CM-10 aims to stimulate a cancer-specific immune response, targeting various malignancies such as melanoma, non-small-cell lung cancer, bladder cancer, gastric cancer, colorectal cancer, and ovarian cancer. cCAM Biotherapeutics is dedicated to developing innovative therapeutic solutions to improve outcomes for cancer patients.
Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.
SMT is a Herzliya Pituach, Israel-based medical device company founded in 2004. SMT is focused on the development and commercialization of procedural tools and accessories for use during TAVI and other complex percutaneous structural heart procedures.
Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.
Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.
Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.
Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.
Insulet Corporation is a medical device company focused on developing, manufacturing, and marketing insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the Omnipod System, consists of a tubeless, disposable insulin infusion device that can be worn for up to three days, and a handheld personal diabetes manager that wirelessly controls the device. The Omnipod System is designed to simplify insulin management, offering features such as pain-free automated cannula insertion and smartphone compatibility for dosage control. Insulet primarily sells its products through independent distributors, pharmacy channels, and directly to patients in the United States, Canada, Europe, and the Middle East. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet has seen significant adoption of its technology, with approximately 425,000 insulin-dependent diabetics using the Omnipod system worldwide since its FDA approval in 2005.
Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.